
Healthcare · BSE
Aptus Pharma Ltd, incorporated in 2010, is engaged in the marketing and distribution of finished pharmaceutical formulations. The company manufactures and distributes a wide range of products across multiple therapeutic areas including antacids and PPIs, pain management, anti-inflammatories, antibiotics, cardiology and antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, and sachets. Its business divisions include Aptus Pharma, which focuses on acute therapies such as anti-infectives and pain management; Aptus CD Care, which specializes in chronic therapies; Aptus Wellcare, which offers wellness and nutraceutical products; and Aptus Global, which caters to the export market. As of March 31, 2025, the company had developed 194 pharmaceutical formulations across more than eleven therapeutic segments. It operates warehouses covering 15,732 sq. feet and 1,989 sq. feet in Ahmedabad, Gujarat. The company’s distribution network consists of 125 direct and sub-distributors supported by a sales team of 54 field personnel, and it employed 70 people as of March 31, 2025.
Price Band
₹65 – ₹70
Issue Size
₹13.02 Cr
Lot Size
2000 shares
GMP
+5.7%
Est. Listing
₹74
at current GMP
Subscribed
21.48x
overall
Open
23 Sep 2025
Close
25 Sep 2025
Allotment
26 Sep 2025
Refund
27 Sep 2025
Demat Credit
28 Sep 2025
Listing
30 Sep 2025
Designated Registrar: Bigshare Services Private Limited
Allotment Date
26 Sep 2025
Basis finalization
Refunds Initiate
27 Sep 2025
Mandate release
Demat Credit
28 Sep 2025
Shares in demat
Listing Debut
30 Sep 2025
Trading begins
Aptus Pharma Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹13.02 Crores. The shares are offered at a price band of ₹65 to ₹70 per equity share on BSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 2000 shares (approx. ₹1,40,000 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Bigshare Services Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2025-09-28, while un-allotted funds or UPI block mandates will be released on 2025-09-27.
Allotment records are updated in batches. If the status is not yet available, please wait a few hours until the basis of allotment is fully finalized.
Since funds are blocked under ASBA/UPI, the bank will automatically release the blocked hold on your funds upon receipt of revocation instructions from the sponsor bank.